Hitherto, Remdesivir has been used to treat Covid patients who are hospitalised and severely ill, with limited success.
Two articles were published in the NEJM yesterday, suggesting that the drug can be used to greater effect if administered at an early stage of infection. This would have implications for folks like us, who may remain vulnerable to Covid after several vaccinations and who may have difficulty in accessing monoclonals and antivirals that are in short supply locally.
The first article nejm.org/doi/full/10.1056/N... reports on a study of Remdesivir for preventing Covid outpatients progressing to severe disease. It was a small, placebo-controlled study with a large precentage of subjects having comorbidities that would make them candidates for severe Covid. The group on Remdesivir had a calculated reduction in risk of 87 %.
The second nejm.org/doi/full/10.1056/N... puts this study in context "The Goldilocks Time for Remdesivir" and in its concluding remarks states "Rapid emergence of variants with adaptive mutations in the spike protein can result in escape from vaccines and monoclonal antibodies, whereas antiviral agents, given the absence of variation in their viral target, are likely to maintain activity, reinforcing the value of antivirals such as remdesivir in curtailing the pandemic".